Results 51 to 60 of about 187,458 (237)
, 2019 Additional file 10: Table S1. Overview of antibodies used for experiments.
Heukels, Peter +13 more
openaire +1 more source
Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
Current Neurology and Neuroscience Reports, 2022 Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) with a chronic and often progressive disease course. The current disease-modifying treatments (DMTs) limit disease progression primarily by dampening immune cell ...
R. Schneider, Jiwon Oh
semanticscholar +1 more source
, 2019 Additional file 9:. Graphic summary of B-cell subset alterations and autoreactive IgA induction in IPF patients. Immature B cells leave the bone marrow as transitional B-cells for further differentiation. Decrease in circulating transitional B-cells together with their increase in IPF lungs suggest homing towards pulmonary tertiary lymphoid organs (TLO)
Heukels, Peter +13 more
openaire +1 more source
Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection [PDF]
, 2016 Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB activation ...
Alves +37 more
core +1 more source
Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
Case Reports in Infectious Diseases, 2016 Cryptococcus is a unique environmental fungus that can cause disease most often in immunocompromised individuals with defective cell-mediated immunity. Chronic lymphocytic leukemia (CLL) is not known to be a risk factor for cryptococcal disease although ...
Koh Okamoto +2 more
doaj +1 more source
, 2019 Additional file 1: Figure S1. No changes of proportions of total B-cells between controls and IPF patients. Flow cytometric quantification of total B-cells (CD19+) in blood, lungs and lymph nodes (LN) as percentage of alive cells. For blood samples data also depicted as absolute number of B-cells per ml blood.
Heukels, Peter +13 more
openaire +1 more source
Blood Cancer Journal, 2022 Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton’s tyrosine kinase (BTK), was designed as an alternative strategy to treat ibrutinib-resistant disease that develops due to C481 kinase domain mutations. The clinical activity of pirtobrutinib has
Burcu Aslan +9 more
semanticscholar +1 more source
, 2019 Additional file 6: Figure S6. Autoreactive IgG and IgM does not correlate with disease progression. Fluorescence intensity for plasma autoreactive IgG (A) and IgM (B) does not correlate with decline in forced vital capacity (FVC) over 1-year period in IPF patients. Correlation coefficients were calculated using Spearmanâ s rank method.
Heukels, Peter +13 more
openaire +1 more source
, 2019 Additional file 7: Figure S7. Gating strategy for B-cell subsets in mice. Representative gating strategy used for mice experiments for the identification of GC B-cells (CD19+CD95+IgDlow), IgA GC B-cells (CD19+CD95+IgDlowIgA+), plasma cells (CD19lowCD138+) and IgA+ plasma cells (CD19lowCD138+IgA+).
Heukels, Peter +13 more
openaire +1 more source
Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer [PDF]
, 2004 X-linked agammaglobulinemia (XLA) is a human immunodeficiency caused by mutations in Bruton tyrosine kinase (Btk) and characterized by an arrest in early B-cell development, near absence of serum immunoglobulin, and recurrent bacteria infections.
Astrakhan, A. +9 more
core +1 more source